Sai Parenterals Limited has secured purchase orders worth USD 11 million from PILL CORP Philippines for the supply of anti-TB products on an exclusivity basis. The contract, valued at ₹104.50 crore at an exchange rate of ₹95, will span a period of 10 years starting June 1, 2026. This long-term agreement is expected to significantly bolster the company's revenue stream through periodic purchase orders released during the contract term.

The disclosure was made to the exchanges under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The company confirmed that the order is from an international entity and that neither the promoter group nor group companies hold any interest in PILL CORP. Furthermore, the transaction does not qualify as a related party transaction.

The contract terms specify that the agreement is valid for ten years from the effective date. It includes provisions for revision or termination with six months' notice prior to expiry or extended expiry. The supply is specifically designated for the Philippines market.

Anil Kumar Karusala, Managing Director, signed the disclosure on behalf of Sai Parenterals Limited. The filing references SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Sai Parenterals Limited has announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a robust performance driven by CDMO exports and the integration of Noumed (Australia). For the full year FY26, the company recorded a Profit After Tax (PAT) of ₹14.37 crore, representing a growth of 45.52% compared to the previous year.

Consolidated Performance

For the financial year ended March 31, 2026, the company reported a revenue of ₹380.99 crore, a significant increase of 140.37% from ₹158.50 crore in FY25. Total income for the year stood at ₹389.51 crore. The company's EBITDA for FY26 was ₹47.21 crore, with a growth of 33.29% year-on-year. The board approved the results during a meeting on May 23, 2026.

Quarterly Highlights

For the quarter ended March 31, 2026 (Q4 FY26), the consolidated revenue from operations was ₹197.93 crore, a jump of 166.65% compared to Q4 FY25. The net profit for the quarter surged to ₹13.25 crore, up 736.04% from ₹1.59 crore in the corresponding quarter of the previous year. EBITDA for the quarter stood at ₹28.97 crore, growing by 366.79%.

Standalone Results

On a standalone basis, Sai Parenteral's Limited reported a revenue of ₹164.99 crore for FY26, reflecting a growth of 30.65% year-on-year. The standalone PAT for the year was ₹16.86 crore, an increase of 63.61% from the previous year. The company attributed this growth to deeper engagement with customers in export markets.

Business and Strategic Updates

The company highlighted the successful acquisition of a 74.6% controlling stake in Australia-based Noumed Pharmaceuticals Pty Limited on November 12, 2025. This acquisition provides access to 451 dossiers and strengthens the company's position in the Australian market. Additionally, Sai Parenterals successfully completed its IPO in March 2026, raising ₹285 crore, and listed on the exchanges on April 02, 2026. The company is executing a capex program of approximately ₹440 crore, expected to be completed by FY27, to support capacity expansion and R&D.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE0H9F01037/bd15a3ace3764c76.pdf